Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover

Wilson, C., Gossiel, F., Leonard, R. et al. (4 more authors) (2016) Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. Journal of Bone Oncology, 5 (1). pp. 43-49. ISSN 2212-1374

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Bone turnover markers; Breast cancer; Chemotherapy; Goserelin; Primary ovarian insufficiency
Dates:
  • Published: March 2016
  • Accepted: 6 February 2016
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine (Sheffield) > Division of Genomic Medicine (Sheffield) > Department of Oncology (Sheffield)
The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 12 Jul 2016 07:51
Last Modified: 12 Jul 2016 07:51
Published Version: http://dx.doi.org/10.1016/j.jbo.2016.02.003
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/j.jbo.2016.02.003
Related URLs:

Share / Export

Statistics